<DOC>
	<DOCNO>NCT03005704</DOCNO>
	<brief_summary>The specific objective study investigate potential normal platelet reverse inhibition platelet aggregation patient treat ticagrelor combination aspirin .</brief_summary>
	<brief_title>Reversal Antiplatelet Effects Ticagrelor Combination With Aspirin , Using Normal Platelets</brief_title>
	<detailed_description>Ticagrelor one three commercially available antiplatelet adenosine diphosphate ( ADP ) antagonist ( two clopidogrel prasugrel ) . They exert antiplatelet effect bind P2Y12 receptor platelet surface . Ticagrelor use combination aspirin prevent treat thrombosis patient acute coronary syndrome , particularly stent implantation . ADP antagonist combine aspirin aspirin block platelet aggregation prevent thromboxane production , block two different pathway lead great efficacy either drug use alone . Recent clinical trial indicate ticagrelor combination aspirin effective prevention thrombotic event patient symptomatic coronary artery disease aspirin combination clopidogrel , cause significantly bleed . The improved efficacy reduce safety occur ticagrelor cause great inhibition ADP-mediated platelet activation . The latter reliably measure laboratory . Management patient bleed take ADP antagonist combination aspirin challenge specific antidote , Platelet transfusion potential reverse effect clopidogrel prasugrel aspirin , finding extrapolate ticagrelor combination aspirin pharmacokinetic pharmacodynamic effect ticagrelor differ . Aspirin , clopidogrel active metabolite , prasugrel active metabolite half-lives 15-20 minute , 30 minute , four hour respectively . They irreversible platelet inhibitor bind permanently block platelet function . After drug elimination , new platelet enter circulation megakaryocyte bone marrow unaffected . Therefore , elimination , newly transfuse platelet potential restore haemostasis . In contrast , ticagrelor , reversible platelet inhibitor , long half-life ( 7.7 14.1 hour ) . As result longer half-life , newly add platelet ( bone marrow transfuse platelet ) inhibit ticagrelor least 24 hour last dose . Therefore , reverse platelet inhibition control excessive bleeding associate ticagrelor platelet transfusion pose great challenge clopidogrel prasugrel . Nevertheless , great efficacy , ticagrelor prefer clopidogrel high risk patient . Previous study platelet transfusion ev vivo mix within 24 hour drug administration show inhibition ADP-mediated platelet activation clopidogrel prasugrel , ticagrelor reverse modulate addition donor platelet . Although reverse platelet inhibitory effect ticagrelor might possible within 24 hour stop drug , possible day follow . This examine . Accordingly , propose perform study systematically evaluate inhibition ADP mediate platelet activation , reliable measure ticagrelor 's antiplatelet activity , donor platelet add platelet subject treat ticagrelor time interval 96 hour last dose .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy subject At least 18 year age No history cardiovascular disease Not take antiplatelet therapy prior participation Known thrombocytopenia , coagulation disorder von Willebrand 's disease , haemophilia Allergy intolerance ticagrelor aspirin ( know ) Consumption drug within precede fourteen day potentially interfere metabolism ticagrelor CYP3A4 , CYP3A Pglycoprotein ( eg , ketoconazole , clarithromycin , nefazodone , ritonavir , atazanavir , diltiazem , amprenavir , aprepitant , erythromycin , fluconazole , verapamil , rifampicin , dexamethasone , phenytoin , carbamazepine , phenobarbital , cyclosporine , simvastatin , atorvastatin , tolbutamide , digoxin ) 21 Previous transfusion pregnancy ( potential alloimmunisation ) Pregnant try conceive , breastfeed Unable unwilling give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Acetylsalicylic acid</keyword>
	<keyword>Platelet transfusion</keyword>
	<keyword>Reversal</keyword>
</DOC>